Assessment of Bioequivalence

 Assessment of the bioequivalence of generic versions of certain reference drugs is complicated by the presence of endogenous levels of said compounds which cannot be distinguished from externally derived compound levels following drug administration. If unaccounted for, the presence of endogenous compound biases towards equivalence in bioequivalence studies of these drugs. Bioequivalence assessments may be complicated further as disposition of the exogenous analogue can be subject to various endogenous processes resulting in nonlinear pharmacokinetics. To overcome these inherent biases a number of different strategies have been employed.

 

  • Solubility based on highest dose strength of an IR product
  • Establishment of bioequivalence criteria
  • Drugs possessing narrow therapeutic index
  • Waivers of In Vivo Study Requirements
  • Biopharmaceutics Classification System (BCS)
  • Topical dosage forms
  • Respiratory dosage forms
  • Transdermal dosage forms
  • Evaluation of highly variable drugs and drug product

Related Conference of Assessment of Bioequivalence

December 14-14, 2020

2nd Pathology and Infectious Disease Conference

Dubai, UAE
March 28-29, 2021

11th Glycobiology World Congress

Vienna, Austria
April 24-24, 2021

2nd International Conference on Nucleic Acids

London, UK
June 11-12, 2021

25th Global Congress on Biotechnology

Berlin, Germany
September 13-14, 2021

17th World Congress on Structural Biology

Prague, Czech Republic
September 27-28, 2021

25th European Biotechnology Congress

Dublin, Ireland

Assessment of Bioequivalence Conference Speakers

Recommended Sessions

Related Journals

Are you interested in